4DS - Anything but Charting, page-19531

While I remain positive on the "tech". The actions of the BOD over the last 12 months needs to be addressed, in relation to disclosure and potential insider trading.

PL2 commenced way back on 27 Jan 2021. Investors were completely in the dark at the time, but this lot incorporated a significant pivot to the use of crystalline PCMO when previously it had been amourphous.

However, BOD discussions must have commenced well before this date and as such, the BOD and senior staff were in possession of market-sensitive information and aware that the risk profile had changed as well as the likely time extension on development.

None of DM, JD or SD should have been permitted to sell without the market being informed of this proposed and eventual pivot to crystalline PCMO.

Desu could also be annoyed, as his work was all in the amorphous field.

While I fully support the pivot, I do not support those who traded with this knowledge. Whether they benefited or not, is not the point.